home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

80.30 -1.24 (-1.52%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 06, 2024

From Biogen Inc.

Via GlobeNewswire

Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals ↗

February 22, 2024

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know ↗

February 01, 2024

Via Benzinga

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines ↗

January 31, 2024

Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.

Via Benzinga

Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts ↗

January 18, 2024

Via Benzinga

Where Ionis Pharmaceuticals Stands With Analysts ↗

November 17, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

October 23, 2023

Via Benzinga

Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study ↗

January 22, 2024

Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission.

Via Benzinga

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

January 08, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

September 27, 2023

Via Benzinga

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies ↗

December 27, 2023

These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024.

Via InvestorPlace

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗

December 22, 2023

Friday, FDA approved AstraZeneca

Via Benzinga

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout. ↗

December 19, 2023

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

November 16, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent? ↗

November 10, 2023

Technical Setup: IONIS PHARMACEUTICALS INC Appears Poised for a Breakout.

Via Chartmill

Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat ↗

November 02, 2023

Via Benzinga

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗

October 17, 2023

Via Benzinga

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

October 02, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Why Ionis Pharmaceuticals Stock Popped Today ↗

September 26, 2023

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant...

Via Benzinga

Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action ↗

September 26, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents...

Via Benzinga

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action

September 26, 2023

Via Investor Brand Network

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com